Antitumor agent-79
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2750233-50-0
- 分子式: C23H19ClN2O
- 分子量:374.86
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
IC50: 0.7 μM (Huh7), 1.4 μM (HepG2), 1.5 μM (SNU475), 7.9 μM (Hep3B), 2.4 μM (FOCUS), 5.2 μM (Hep40), 6.5 μM (PLC-PRF-5), 3.7 μM (Mahlavu), 0.9 μM (MCF7), 0.9 μM (MDA-MB231), 1.0 μM (MDA-MB468), 1.8 μM (SKBR3), 5.5 μM (ZR75), 7.6 μM (MCF10A)[1]
体外実験
Antitumor agent-79 (0.15-40 μM; 72 h) shows in vitro growth inhibitory activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM[1]. Antitumor agent-79 (5 μM; 48 h) induces cell apoptosis by increasing the PARP cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231. MDA-MB468, SKBR3, ZR75 and MCF10A cell lines
-
Concentration:0.15-40 μM
-
Incubation Time:72 hours
-
Result:Time and dose-dependent showed cytotoxicity to hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7, 1.4, 1.5, 7.9, 2.4, 5.2, 6.5, 3.7, 0.9, 0.9, 1.0, 1.8, 5.5 and 7.6 μM for Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231, MDA-MB468, SKBR3, ZR75 and MCF10A cells, respectively.
-
Cell Line:Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells
-
Concentration:5 μM
-
Incubation Time:48 hours
-
Result:Increased the PARP cleavage in both breast cancer cells (MCF7 and MDA-MB-231) and hepatocellular carcinoma cells (Mahlavu).
-
Cell Line:Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells
-
Concentration:5 μM
-
Incubation Time:48 hours
-
Result:Induced cell apoptosis of cancer cells.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6−8 weeks old male athymic nude mice with hepatocellular carcinoma (Mahlavu cells) and breast (MDA MB-231 cells) xenografts[1]
-
Dosage:40 mg/kg
-
Administration:Oral gavage; 40 mg/kg; twice a week for 4 weeks
-
Result:Significantly reduced the tumor volume following 4 weeks treatment with 40% reductions of tumor volumes in the Mahlavu xenografts. Resulted in about a 50% decreased in tumor volumes as compared to the control group in MDA-MB-231 xenografts. Showed well tolerated in vivo and neither significant bodyweight loss nor toxic effects or mortality were observed.
化学情報
-
CAS 番号 2750233-50-0
-
分子量 374.86
-
分子式 C23H19ClN2O
-
SMILES
CC1=CC=CC=C1COC2=CC=C(C3=CC=NN3C4=CC=C(Cl)C=C4)C=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Antitumor agent-79 関連分類
HY-151618 関連分類
Powered by Bioz